natgillin/translations-raw huggingface dataset:
It is therefore appropriate to include hymexazol in Annex I, in order to ensure that in all Member States the authorisations of plant protection products containing this active substance can be granted in accordance with the provisions of that Directive.
Zato je primerno vključiti himeksazol v Prilogo I, da se v vseh državah članicah v skladu z določbami navedene direktive lahko registrirajo fitofarmacevtska sredstva, ki vsebujejo to aktivno snov.
Therefore, it is appropriate to require that the applicant submit further information confirming the nature of residues in root crops and to confirm the risk for granivorous birds and mammals.
Zato je primerno zahtevati, da vlagatelj predloži dodatne informacije o naravi ostankov v korenovkah in gomoljnicah ter potrdi tveganje za semenojede ptice in sesalce.
The line concerning hymexazol in the Annex to Decision 2008/934/EC is deleted.
V Prilogi k Odločbi 2008/934/ES se črta vrstica, ki zadeva himeksazol.
Member States shall in accordance with Directive 91/414/EEC, where necessary, amend or withdraw existing authorisations for plant protection products containing hymexazol as an active substance by 1 December 2011.
Države članice v skladu z Direktivo 91/414/EGS do 1. decembra 2011 po potrebi spremenijo ali prekličejo obstoječe registracije fitofarmacevtskih sredstev, ki vsebujejo himeksazol kot aktivno snov.
By that date they shall in particular verify that the conditions in Annex I to that Directive relating to hymexazol are met, with the exception of those identified in part B of the entry concerning that active substance, and that the holder of the authorisation has, or has access to, a dossier satisfying the requirements of Annex II to that Directive in accordance with the conditions of Article 13 of that Directive.
Do navedenega datuma zlasti preverijo, ali so pogoji iz Priloge I k navedeni direktivi v zvezi s himeksazolom, z izjemo tistih iz dela B besedila o navedeni aktivni snovi, izpolnjeni in ali ima imetnik registracije dokumentacijo ali dostop do dokumentacije, ki izpolnjuje zahteve iz Priloge II k navedeni direktivi v skladu s pogoji iz člena 13 navedene direktive.
By way of derogation from paragraph 1, for each authorised plant protection product containing hymexazol as either the only active substance or as one of several active substances all of which were listed in Annex I to Directive 91/414/EEC by 31 May 2011 at the latest, Member States shall re-evaluate the product in accordance with the uniform principles provided for in Annex VI to Directive 91/414/EEC, on the basis of a dossier satisfying the requirements of Annex III to that Directive and taking into account part B of the entry in Annex I to that Directive concerning hymexazol.
Z odstopanjem od odstavka 1 države članice znova ocenijo vsako registrirano fitofarmacevtsko sredstvo, ki vsebuje himeksazol kot edino aktivno snov ali kot eno od več aktivnih snovi, vključenih v Prilogo I k Direktivi 91/414/EGS najpozneje do 31. maja 2011, v skladu z enotnimi načeli iz Priloge VI k Direktivi 91/414/EGS na podlagi dokumentacije, ki izpolnjuje zahteve iz Priloge III k navedeni direktivi, in ob upoštevanju dela B besedila o himeksazolu iz Priloge I k navedeni direktivi.
in the case of a product containing hymexazol as the only active substance, where necessary, amend or withdraw the authorisation by 31 May 2015 at the latest; or
če sredstvo vsebuje himeksazol kot edino aktivno snov, najpozneje do 31. maja 2015 po potrebi spremenijo ali prekličejo registracijo ali
in the case of a product containing hymexazol as one of several active substances, where necessary, amend or withdraw the authorisation by 31 May 2015 or by the date fixed for such an amendment or withdrawal in the respective Directive or Directives which added the relevant substance or substances to Annex I to Directive 91/414/EEC, whichever is the latest.
če sredstvo vsebuje himeksazol kot eno izmed več aktivnih snovi, registracijo po potrebi spremenijo ali prekličejo najpozneje do 31. maja 2015 ali do datuma, določenega za takšno spremembo ali preklic v ustreznih direktivah, s katerimi so bile zadevne snovi dodane v Prilogo I k Direktivi 91/414/EGS, pri čemer se upošteva poznejši datum.
European Food Safety Authority; Conclusion on the peer review of the pesticide risk assessment of the active substance hymexazol.
[6] Evropska agencija za varnost hrane; Sklep o strokovnem pregledu ocene tveganja pesticidov z aktivno snovjo himeksazol.
CIPAC No: 528
Št. CIPAC: 528
5-methylisoxazol-3-ol (or 5-methyl-1,2-oxazol-3-ol)
5-methylisoxazol-3-ol (ali 5-methyl-1,2-oxazol-3-ol)
Only uses as fungicide for seed pelleting of sugar beets in professional seed treatment facilities may be authorised.
Registrira se lahko le kot fungicid za peletiranje semena sladkorne pese v profesionalnih objektih za tretiranje semena.
For the implementation of the uniform principles of Annex VI, the conclusions of the review report on hymexazol, and in particular Appendices I and II thereof, as finalised in the Standing Committee on the Food Chain and Animal Health on 23 November 2010 shall be taken into account.
Za izvajanje enotnih načel iz Priloge VI se upoštevajo sklepi poročila o pregledu za himeksazol, in zlasti dodatkov I in II k poročilu, kot je bilo dokončno oblikovano v Stalnem odboru za prehranjevalno verigo in zdravje živali 23. novembra 2010.
Conditions of authorisation shall include protective measures, where appropriate,
Pogoji registracije po potrebi vključujejo varnostne ukrepe;
the risk to granivorous birds and mammals.
tveganje za semenojede ptice in sesalce.
The Member States concerned shall request the submission of confirmatory information as regards the nature of residues in root crops and the risk for granivorous birds and mammals.
Zadevne države članice zahtevajo predložitev potrditvenih informacij glede narave ostankov v korenovkah in gomoljnicah ter tveganja za semenojede ptice in sesalce.
The Member States concerned shall ensure that the applicant submits such confirmatory information to the Commission by 31 May 2013.’
Zadevne države članice zagotovijo, da vlagatelj takšne potrditvene informacije predloži Komisiji do 31. maja 2013.“
Without prejudice to the obligations defined by Directive 91/414/EEC as a consequence of including an active substance in Annex I, Member States should be allowed a period of six months after inclusion to review existing authorisations of plant protection products containing hymexazol to ensure that the requirements laid down by Directive 91/414/EEC, in particular in its Article 13 and the relevant conditions set out in Annex I, are satisfied. Member States should vary, replace or withdraw, as appropriate, existing authorisations, in accordance with the provisions of Directive 91/414/EEC.
Brez poseganja v obveznosti iz Direktive 91/414/EGS, ki izhajajo iz vključitve aktivne snovi v Prilogo I, je državam članicam treba omogočiti, da v šestih mesecih po vključitvi snovi pregledajo obstoječe registracije fitofarmacevtskih sredstev, ki vsebujejo himeksazol, da zagotovijo izpolnjevanje zahtev iz Direktive 91/414/EGS, zlasti iz člena 13 in ustreznih pogojev iz Priloge I. Države članice v skladu z določbami Direktive 91/414/EGS obstoječe registracije po potrebi spremenijo, nadomestijo ali prekličejo.
Decision 2008/934/EC provides for the non-inclusion of hymexazol and the withdrawal of authorisations for plant protection products containing that substance by 31 December 2011.
Odločba 2008/934/ES določa nevključitev himeksazola in preklic registracij fitofarmacevtskih sredstev, ki vsebujejo navedeno snov, do 31. decembra 2011.
It is necessary to delete the line concerning hymexazol in the Annex to that Decision.
V Prilogi k navedeni odločbi je treba črtati vrstico, ki zadeva himeksazol.
Commission Directive 2011/6/EU
Direktiva Komisije 2011/6/EU
amending Council Directive 91/414/EEC to include buprofezin as active substance
o spremembi Direktive Sveta 91/414/EGS zaradi vključitve buprofezina kot aktivne snovi
That list included buprofezin.
Navedeni seznam je vključeval buprofezin.
By Commission Decision 2008/771/EC [4] it was decided not to include buprofezin in Annex I to Directive 91/414/EEC.
Z Odločbo Komisije 2008/771/ES [4] je bilo odločeno, da se buprofezin ne vključi kot aktivna snov v Prilogo I k Direktivi 91/414/EGS.
Pursuant to Article 6(2) of Directive 91/414/EEC the original notifier (hereinafter ‘the applicant’) submitted a new application requesting the accelerated procedure to be applied, as provided for in Articles 14 to 19 of Commission Regulation (EC) No 33/2008 of 17 January 2008 laying down detailed rules for the application of Council Directive 91/414/EEC as regards a regular and an accelerated procedure for the assessment of active substances which were part of the programme of work referred to in Article 8(2) of that Directive but have not been included into its Annex I [5].
Prvotni prijavitelj (v nadaljnjem besedilu: vlagatelj) je v skladu s členom 6(2) Direktive 91/414/EGS vložil nov zahtevek za uporabo pospešenega postopka iz členov od 14 do 19 Uredbe Komisije (ES) št. 33/2008 z dne 17. januarja 2008 o podrobnih pravilih za izvajanje Direktive Sveta 91/414/EGS glede rednega in pospešenega postopka za oceno aktivnih snovi, ki so bile del delovnega programa iz člena 8(2) navedene direktive, vendar niso bile vključene v Prilogo I [5].
The application was submitted to the United Kingdom, which had been designated rapporteur Member State by Regulation (EC) No 33/2008.
Zahtevek je bil predložen Združenemu kraljestvu, ki je bilo z Uredbo (ES) št. 33/2008 imenovano za državo članico poročevalko.
The specification of the active substance and the supported uses are the same as those that were the subject of Decision 2008/771/EC.
Specifikacija aktivne snovi in podprte uporabe so enake kot v Odločbi Komisije 2008/771/ES.
The United Kingdom evaluated the new information and data submitted by the applicant and prepared an additional report in August 2009.
Združeno kraljestvo je ocenilo nove informacije in podatke, ki jih je predložil vlagatelj, ter avgusta 2009 pripravilo dodatno poročilo.
It communicated that report to the European Food Safety Authority (hereinafter ‘the Authority’) and to the Commission on 21 August 2009.
Navedeno poročilo je 21. avgusta 2009 predložilo Evropski agenciji za varnost hrane (v nadaljnjem besedilu: Agencija) in Komisiji.
In accordance with Article 20(1) of Regulation (EC) No 33/2008 and at the request of the Commission, the additional report was peer reviewed by the Member States and the Authority.
V skladu s členom 20(1) Uredbe (ES) št. 33/2008 in na zahtevo Komisije so dodatno poročilo pregledali strokovnjaki držav članic in Agencije.
The Authority then presented its conclusion on buprofezin to the Commission on 21 May 2010 [6].
Agencija je nato 21. maja 2010 [6] svoje sklepe o buprofezinu predstavila Komisiji.
The draft assessment report, the additional report and the conclusion of the Authority were reviewed by the Member States and the Commission within the Standing Committee on the Food Chain and Animal Health and finalised on 23 November 2010 in the format of the Commission review report for buprofezin.
Osnutek poročila o oceni, dodatno poročilo in sklep Agencije so države članice in Komisija pregledale v okviru Stalnega odbora za prehranjevalno verigo in zdravje živali ter končno različico pripravile 23. novembra 2010 v obliki poročila Komisije o pregledu glede buprofezina.
Those concerns were, in particular, the impossibility to perform a reliable consumer exposure assessment because of lack of data to determine an appropriate residue definition.
Ti pomisleki so zadevali zlasti nezmožnost izvedbe ustrezne ocene izpostavljenosti potrošnikov, saj manjkajo podatki za ustrezno opredelitev ostankov.
The new information submitted by the applicant enabled a consumer exposure assessment.
Nove informacije, ki jih je predložil vlagatelj, so omogočile oceno izpostavljenosti potrošnikov.
The information currently available indicates that the risk to consumers is acceptable.
V skladu z razpoložljivimi informacijami je tveganje za potrošnike sprejemljivo.
It has appeared from the various examinations made that plant protection products containing buprofezin may be expected to satisfy, in general, the requirements laid down in Article 5(1)(a) and (b) of Directive 91/414/EEC, in particular with regard to the uses which were examined and detailed in the Commission review report.
Različne preiskave so pokazale, da se za fitofarmacevtska sredstva, ki vsebujejo buprofezin, lahko pričakuje, da na splošno izpolnjujejo zahteve iz člena 5(1)(a) in (b) Direktive 91/414/EGS, zlasti v zvezi z uporabami, ki so bile preučene in podrobno navedene v poročilu Komisije o pregledu.
It is therefore appropriate to include buprofezin in Annex I, in order to ensure that in all Member States the authorisations of plant protection products containing this active substance may be granted in accordance with the provisions of that Directive.
Zato je primerno vključiti buprofezin v Prilogo I, da se v vseh državah članicah v skladu z določbami navedene direktive lahko registrirajo fitofarmacevtska sredstva, ki vsebujejo to aktivno snov.
Without prejudice to that conclusion, it is appropriate to obtain confirmatory information on certain specific points.
Brez poseganja v navedeni sklep je primerno pridobiti potrditvene informacije o nekaterih posameznih točkah.
Therefore, it is appropriate to require that the applicant submit further information to confirm the processing and conversion factors in the consumer risk assessment.
Zato je primerno zahtevati, da vlagatelj predloži dodatne informacije, ki potrjujejo predelovalne faktorje in faktorje pretvorbe v oceni tveganja za potrošnike.
OJ L 263, 2.10.2008, p. 18.
UL L 263, 2.10.2008, str. 18.
European Food Safety Authority: Conclusion on the peer review of the pesticide risk assessment of the active substance buprofezin EFSA Journal 2010; 8(6):1624.
[6] Evropska agencija za varnost hrane: Sklep o strokovnem pregledu ocene tveganja pesticidov z aktivno snovjo buprofezin. EFSA Journal 2010; 8(6):1624.
CAS No: 953030-84-7
Št. CAS: 953030-84-7
CIPAC No: 681
Št. CIPAC: 681
1 February 2011
1. februar 2011
31 January 2021
31. januar 2021
For the implementation of the uniform principles of Annex VI the conclusions of the review report on buprofezin, and in particular Appendices I and II thereof, as finalised in the Standing Committee on the Food Chain and Animal Health on 23 November 2010, shall be taken into account.
Za izvajanje enotnih načel iz Priloge VI se upoštevajo sklepi poročila o pregledu za buprofezin, in zlasti dodatkov I in II k poročilu, kot je bilo dokončno oblikovano v Stalnem odboru za prehranjevalno verigo in zdravje živali 23. novembra 2010.
the operators’ and workers’ safety and ensure that conditions of use impose adequate personal protective equipment where appropriate;
varnost izvajalcev in delavcev ter zagotovitev, da je v pogojih uporabe po potrebi predpisana uporaba ustrezne osebne zaščitne opreme;
the dietary exposure of consumers to the buprofezin (aniline) metabolites in processed food;
prehransko izpostavljenost potrošnikov metabolitom buprofezina (anilin) v predelani hrani;
the application of an appropriate waiting period for rotational crops in greenhouses;
uporabo ustrezne čakalne dobe za posevke, ki sledijo v kolobarju, v rastlinjakih;
the risk to aquatic organisms and ensure that conditions of use impose adequate risk mitigation measures, where appropriate.
tveganje za vodne organizme in zagotovitev, da so v pogojih uporabe po potrebi predpisani ustrezni ukrepi za zmanjšanje tveganja.
The Member States concerned shall request the submission of confirmatory information as regards the processing and conversion factors for consumer risk assessment.
Zadevne države članice zahtevajo predložitev potrditvenih informacij glede predelovalnih faktorjev in faktorjev pretvorbe za oceno tveganja za potrošnike.
The Member States concerned shall ensure that the applicant submits such confirmatory information to the Commission by 31 January 2013.’
Zadevne države članice zagotovijo, da vlagatelj take potrditvene informacije predloži Komisiji do 31. januarja 2013.“
Member States shall bring into force the laws, regulations and administrative provisions necessary to comply with this Directive by 31 July 2011 at the latest.
Države članice sprejmejo zakone in druge predpise, potrebne za uskladitev s to direktivo, najpozneje do 31. julija 2011.
Directive 2011/7/EU of the European Parliament and of the Council
Direktiva 2011/7/EU Evropskega parlamenta in Sveta
of 16 February 2011
z dne 16. februarja 2011
on combating late payment in commercial transactions
o boju proti zamudam pri plačilih v trgovinskih poslih
A number of substantive changes are to be made to Directive 2000/35/EC of the European Parliament and of the Council of 29 June 2000 on combating late payment in commercial transactions [3].
Potrebnih je več vsebinskih sprememb Direktive 2000/35/ES Evropskega parlamenta in Sveta z dne 29. junija 2000 o boju proti zamudam pri plačilih v trgovinskih poslih [3].
It is desirable, for reasons of clarity and rationalisation, that the provisions in question be recast.
Zaradi jasnosti in racionalizacije je zaželeno, da se zadevne določbe prenovijo.
Most goods and services are supplied within the internal market by economic operators to other economic operators and to public authorities on a deferred payment basis whereby the supplier gives its client time to pay the invoice, as agreed between parties, as set out in the supplier’s invoice or as laid down by law.
Gospodarski subjekti večino blaga in storitev na notranjem trgu dobavljajo drugim gospodarskim subjektom in javnim organom na podlagi odloga plačila, pri čemer dobavitelj svoji stranki da čas, da plača račun po dogovoru med stranema, kot je določeno v dobaviteljevem računu ali v skladu z zakonom.
Many payments in commercial transactions between economic operators or between economic operators and public authorities are made later than agreed in the contract or laid down in the general commercial conditions.
Veliko plačil v trgovinskih poslih med gospodarskimi subjekti ali med gospodarskimi subjekti in javnimi organi se opravi pozneje, kot je dogovorjeno v pogodbi ali določeno v splošnih trgovinskih pogojih.
Although the goods are delivered or the services performed, many corresponding invoices are paid well after the deadline.
Kljub dostavi blaga ali opravljenim storitvam je veliko zadevnih računov plačanih po roku.
Such late payment negatively affects liquidity and complicates the financial management of undertakings.
Takšne zamude pri plačilih negativno vplivajo na likvidnost in zapletajo finančno upravljanje podjetij.
It also affects their competitiveness and profitability when the creditor needs to obtain external financing because of late payment.
Prav tako vplivajo na njihovo konkurenčnost in dobičkonosnost, ko upnik zaradi zamud pri plačilih potrebuje zunanje financiranje.
The risk of such negative effects strongly increases in periods of economic downturn when access to financing is more difficult.
Tveganje zaradi takšnih negativnih učinkov se močno poveča v obdobjih gospodarskega upada, ko je dostop do financiranja težji.
Judicial claims related to late payment are already facilitated by Council Regulation (EC) No 44/2001 of 22 December 2000 on jurisdiction and the recognition and enforcement of judgments in civil and commercial matters [4], Regulation (EC) No 805/2004 of the European Parliament and of the Council of 21 April 2004 creating a European Enforcement Order for uncontested claims [5], Regulation (EC) No 1896/2006 of the European Parliament and of the Council of 12 December 2006 creating a European order for payment procedure [6] and Regulation (EC) No 861/2007 of the European Parliament and of the Council of 11 July 2007 establishing a European Small Claims Procedure [7].
Vlaganje sodnih zahtevkov, povezanih z zamudami pri plačilih, je že olajšano z Uredbo Sveta (ES) št. 44/2001 z dne 22. decembra 2000 o pristojnosti in priznavanju ter izvrševanju sodnih odločb v civilnih in gospodarskih zadevah [4], Uredbo (ES) št. 805/2004 Evropskega parlamenta in Sveta z dne 21. aprila 2004 o uvedbi evropskega naloga za izvršbo nespornih zahtevkov [5], Uredbo (ES) št. 1896/2006 Evropskega parlamenta in Sveta z dne 12. decembra 2006 o uvedbi postopka za evropski plačilni nalog [6] ter Uredbo (ES) št. 861/2007 Evropskega parlamenta in Sveta z dne 11. julija 2007 o uvedbi evropskega postopka v sporih majhne vrednosti [7].
However, in order to discourage late payment in commercial transactions, it is necessary to lay down complementary provisions.
Vendar je za odvračanje od zamud pri plačilih v trgovinskih poslih treba določiti dopolnilne določbe.
Undertakings should be able to trade throughout the internal market under conditions which ensure that transborder operations do not entail greater risks than domestic sales.
Podjetjem bi moralo biti omogočeno trgovati na celotnem notranjem trgu v razmerah, ki zagotavljajo, da čezmejno poslovanje ne pomeni večjega tveganja kot domači promet.
Distortions of competition would ensue if substantially different rules applied to domestic and transborder operations.
Če bi za domače in čezmejno poslovanje veljala bistveno drugačna pravila, bi prišlo do izkrivljanja konkurence.
In its Communication of 25 June 2008 entitled ‘ “Think Small First” — A “Small Business Act” for Europe’, the Commission emphasised that small and medium-sized enterprises’ (SMEs) access to finance should be facilitated and that a legal and business environment supportive of timely payments in commercial transactions should be developed.
Komisija je v Sporočilu z dne 25. junija 2008 z naslovom „‚Najprej pomisli na male‛ – ‚Akt za mala podjetja‛ za Evropo“ poudarila, da bi bilo malim in srednje velikim podjetjem (MSP) treba olajšati dostop do financiranja in da bi bilo treba razviti pravno in poslovno okolje, ki spodbuja pravočasno plačevanje v trgovinskih poslih.
It should be noted that public authorities have a special responsibility in this regard.
Omeniti bi bilo treba, da imajo javni organi glede tega posebno odgovornost.
The criteria for the definition of SMEs are set out in Commission Recommendation 2003/361/EC of 6 May 2003 concerning the definition of micro, small and medium-sized enterprises [8].
Merila za opredelitev MSP so navedena v Priporočilu Komisije 2003/361/ES z dne 6. maja 2003 o opredelitvi mikro, malih in srednje velikih podjetij [8].
One of the priority actions of the Commission Communication of 26 November 2008 entitled ‘European Economic Recovery Plan’ is the reduction of administrative burdens and the promotion of entrepreneurship by, inter alia, ensuring that, as a matter of principle, invoices, including to SMEs, for supplies and services are paid within 1 month to ease liquidity constraints.
Eden od prednostnih ukrepov Sporočila Komisije z dne 26. novembra 2008 z naslovom „Evropski načrt za oživitev gospodarstva“ je zmanjšanje administrativnega bremena in spodbujanje podjetništva, med drugim z zagotavljanjem, da se računi za dobavo in storitve, vključno z računi MSP, zaradi zmanjšanja likvidnostnih omejitev načeloma plačajo v enem mesecu.
The scope of this Directive should be limited to payments made as remuneration for commercial transactions.
Področje uporabe te direktive bi moralo biti omejeno na plačila kot prejemke v zvezi s trgovinskimi posli.
This Directive should not regulate transactions with consumers, interest in connection with other payments, for instance payments under the laws on cheques and bills of exchange, or payments made as compensation for damages including payments from insurance companies.
Ta direktiva ne bi smela urejati poslovanja s potrošniki, obresti v zvezi z drugimi plačili, na primer plačili glede na zakonodajo o čekih in menicah ali plačili kot nadomestili za škodo, vključno s plačili zavarovalnic.
Furthermore, Member States should be able to exclude debts that are subject to insolvency proceedings, including proceedings aimed at debt restructuring.
Državam članicam bi moralo biti tudi omogočeno, da izključijo dolgove, ki so predmet postopkov zaradi insolventnosti, vključno s postopki za prestrukturiranje dolga.